Is Tempus AI, Inc. (TEM) a Buy, Sell, or Hold?
NASDAQ : TEM
Tempus AI, Inc.
$53.59 USD
-$3.66 (-6.39%)
- Volume
- 4.72M
- Average Volume
- 6.38M
- Market Capitalization
- $9.35B
- P/E Ratio
- -31.34
- Dividend Yield
- 0.00%
- Price Target
- $64.50
- Year High
- $104.32
- Year Low
- $41.73
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.31
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Eric Lefkofsky |
| Industry | Medical - Healthcare Information Services |
| Sector | Healthcare |
| Current Symbol | TEM |
| CUSIP | 88023B103 |
| CIK | 0001717115 |
| Web | https://www.tempus.com |
| Phone | 800 976 5448 |
| Currency | USD |
| Employees | 3800 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 3.17 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.31 |
| Quick Ratio | 3.15 |
| Cash Ratio | 1.64 |
Sales & Book Value
| Annual Sales | $1.27B |
| Price / Sales | 6.86 |
| Cash Flow | -1.21 |
| Price / Cash Flow | -43.20 |
| Price / Book | 23.02 |
Price Target and Rating
| Average Stock Price Forecast | $64.50 |
| High Stock Price Forecast | $100.00 |
| Low Stock Price Forecast | $59.00 |
| Forecast Upside/Downside | -16.91% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 13 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.41 |
| Trailing P/E Ratio | -31.34 |
| PEG Ratio | -2.67 |
| P/E Growth | -2.67 |
| Net Income | -$245.03M |
| Net Margin | -22.20% |
| Pretax Margin | -22.61% |
| Return on Equity | -70.24% |
| Return on Assets | -14.19% |
Financials Score
| AltmanZ Score | 2.51 |
| Piotroski Score | 3.00 |
| Working Capital | 735.99M |
| Total Assets | 2.14B |
| Ebit | -243.75M |
| Market Cap | 9.99B |
| Total Liabilities | 1.72B |
Poll Results
About Tempus AI, Inc. (NASDAQ:TEM) Stock
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinica ... l assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
2026-07-16 08:30:00
CHICAGO--(BUSINESS WIRE)--Tempus, a technology company leading the adoption of AI to advance precision medicine, today highlighted results of the Articulate Pro study, published in Nature Digital Medicine, evaluating the use of AI to assist pathologists in prostate biopsy reporting. The study was a real-world evaluation of the Paige Prostate Suite, an integral part of the Tempus intelligent diagnostics ecosystem, and its integration into routine clinical workflows. AI-assisted review supported.
Tempus AI: Building Ultimate Healthcare Data Dominance
2026-07-13 15:27:06
Tempus AI, Inc. earns a Strong Buy rating due to its transformation into a healthcare data giant with high-margin, rapidly growing data services. TEM's Q1 2026 data segment revenue surged 40% YoY to $87M, with robust bookings and visibility, positioning the segment for $500M+ revenue in 2026. MRD testing volume rose 500% YoY, driven by a highly sensitive, reimbursed test partnership with Personalis, fueling valuable data acquisition for pharma clients.
Squeeze Watch: 10 Stocks Bears Love to Hate Most Right Now
2026-07-13 14:29:04
Short‑interest screens are lighting up with a tight cluster of mid‑ and large‑cap names where bearish bets have gone all‑in, turning these stocks into live‑wire squeeze candidates rather than sleepy laggards.
Tempus to Report Second Quarter 2026 Financial Results on July 30
2026-07-09 09:00:00
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced it will report financial results for the second quarter ended June 30, 2026, on Thursday, July 30, 2026. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss the results and provide a business update. The call will be led by Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The.
Tempus AI: Buy On Diagnostics Momentum And AI Platform Expansion
2026-06-30 03:50:49
Tempus receives a Buy rating, leveraging a unique AI-driven diagnostics and data platform with expanding FDA-approved offerings. Recent FDA approval for xT CDx's tumor-only indication and the upcoming xH assay broaden TEM's clinical reach and addressable markets. AI-powered Lens and Next platforms drive adoption among top biopharma and improve clinical outcomes, reinforcing TEM's data flywheel and competitive moat.
2026-06-25 08:30:00
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a research collaboration with Angiosarcoma Awareness, Inc. to accelerate data-driven research in angiosarcoma, one of the rarest and most aggressive cancers. Angiosarcoma is a rare malignant tumor that starts in endothelial cells, which form the inner lining of blood vessels. It is known for its aggressive behavior, rapid progres.
Should You Retain Tempus AI Stock In Your Portfolio Now?
2026-06-18 13:51:00
TEM's diagnostics growth and expanding data deals support momentum, but sizable GAAP losses and execution challenges could keep shares volatile.
Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms
2026-06-16 17:07:59
Tempus AI (TEM) has consolidated near trend lows for four months, forming a double bottom with breakout resistance at $54.75 and a first target near $64.54.
Frequently Asked Questions
-
What is the current Tempus AI, Inc. (TEM) stock price?
-
Tempus AI, Inc.(NASDAQ:TEM) stock price is $53.59 in the last trading session. During the trading session, TEM stock reached the peak price of $104.32 while $41.73 was the lowest point it dropped to. The percentage change in TEM stock occurred in the recent session was --6.39% while the dollar amount for the price change in TEM stock was -$3.66.
-
TEM's industry and sector of operation?
-
The NASDAQ listed TEM is part of Medical - Healthcare Information Services industry that operates in the broader Healthcare sector.
-
Who are the executives of TEM?
-
Ryan Fukushima | Chief Executive Officer of Data & Apps
Ryan Bartolucci | Chief Accounting Officer
Shane Colley | Chief Technology Officer
Christina Antoniou | Senior Vice President & Head of Corporate Development
Lauren R. Silvis | Senior Vice President of External Affairs -
How many employees does TEM have?
-
Number of TEM employees currently stands at 3800. TEM operates from 600 West Chicago Avenue, Chicago, IL 60654, US.
-
Link for TEM official website?
-
Official Website of TEM is: https://www.tempus.com
-
How do I contact TEM?
-
TEM could be contacted at phone #800 976 5448 and can also be accessed through its website. TEM operates from 600 West Chicago Avenue, Chicago, IL 60654, US.
-
How many shares of TEM are traded daily?
-
The average number of TEM shares traded daily for last 3 months was 6.38M.
-
What is the market cap of TEM currently?
-
The market value of TEM currently stands at $9.35B with its latest stock price at $53.59